SNNLive caught up with Thomas Equels, CEO AIM ImmunoTech Inc. (NYSE American: AIM), via Zoom to discuss (Click the time stamp to jump to each answer, or watch it all): 1:16 AIM ImmunoTech’s approach and progress with Ampligen to combat…